dalteparin has been researched along with Pleural Effusion, Malignant in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Pleural Effusion, Malignant: Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gamperl, H | 1 |
| Plattfaut, C | 1 |
| Freund, A | 1 |
| Quecke, T | 1 |
| Theophil, F | 1 |
| Gieseler, F | 1 |
1 other study available for dalteparin and Pleural Effusion, Malignant
| Article | Year |
|---|---|
Extracellular vesicles from malignant effusions induce tumor cell migration: inhibitory effect of LMWH tinzaparin.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Movement; Colorectal Neoplasms; Endothelium, Vascular; Epit | 2016 |